Alta Partners
Edit

Alta Partners

https://www.altapartners.com
Last activity: 15.01.2025
Active
Invests in categories: HealthTechDevelopmentProductHumanMedtechLifeCareBioTechPlatformResearch
Alta Partners is a leading healthcare and life sciences venture capital firm, helping entrepreneurs build high-impact companies since 1996.
Portfolio
32
Mentions
53
Employees: 1-10
Investment Type: Venture Capital
Investment Stage: Series A; Series D
.

Portfolio 32

DateNameWebsiteTotal RaisedLocation
31.12.2022Free Marke...freemarkethealth.com$33.5MUnited Sta...
31.12.2022BetterVet,...bettervet.com$40MUnited Sta...
31.12.2022MBrace The...mbracetrx.com$85M-
25.07.2022Everside H...eversidehealth.com$164MUnited Sta...
24.06.2022DEM Biopha...dembiopharma.com$70MUnited Sta...
28.04.2022Kelonia Th...keloniatx.com$50MUnited Sta...
04.06.2021Transcaren...transcarent.ai$184MUnited Sta...
04.06.2021ImmuneIDimmuneidrx.com$50MUnited Sta...
03.03.2021DispatchHe...dispatchhealth.com$1.01BUnited Sta...
23.10.2020Be Biophar...bebiopharma.com$60MUnited Sta...
Show more

Mentions in press and media 53

DateTitleDescription
15.01.2025Be Bio Closes $92M Series C FinancingBe Bio, a Cambridge, MA-based company which specializes in B Cell Medicines (BCMs), raised $92M in Series C funding. The round was led by Nextech with existing investors including ARCH Venture Partners, Atlas Venture, RA Capital Management,...
28.10.2024Be Biopharma: Pioneering the Future of Genetic Medicine with $82 Million in New FundingIn the ever-evolving landscape of biotechnology, Be Biopharma stands out like a lighthouse in a storm. This Cambridge, Massachusetts-based company has just secured $82 million in funding, a financial windfall that promises to propel its inn...
25.10.2024Be Bio: $82 Million Raised To Discover And Develop Engineered B Cell MedicinesBe Biopharma – a leader in the discovery and development of engineered B Cell Medicines (BCMs) – announced key milestones alongside a new round of funding as its lead program BE-101 for Hemophilia B, enters the clinic, and its second develo...
09.09.2024Пионер ксенотрансплантации eGenesis собрал $191 млн для генно-редактированных органов свиньиКомпания eGenesis уже попала в заголовки новостей благодаря трансплантации органов свиньи. В марте 2024 года eGenesis объявила о первой в мире успешной пересадке почки свиньи живому пациенту. Трансплантация была одобрена FDA в рамках расшир...
04.09.2024eGenesis Raises $191M in Series B FundingeGenesis, a Cambridge, MA-based biotechnology company developing human-compatible engineered organs to address the global organ shortage, raised $191M in Series B funding. The round was led by Lux Capital, with participation from existing i...
04.09.2024eGenesis: $191 Million (Series D) Secured To Develop Engineered Organs For Addressing Transplant ShortageseGenesis, a biotechnology company that is developing human-compatible engineered organs to address the global organ shortage, announced today the closing of a $191 million Series D financing. The funding was led by Lux Capital, with partici...
02.05.2024Transcarent raises $126M to accelerate AI capabilitiesThis round values the company at $2.2 billion As everyone knows, the amount that the U.S. spends on healthcare is astronomical: in 2022 the number reached $4.4 trillion and it projected to reach $7.2 trillion in 2031, when it will account f...
13.09.2022Novome gets $43.5M boost for its engineered microbiome therapiesNovome Biotechnologies — a South San Francisco-based biotech focused on genetically engineered microbial medicines (GEMMs) — raised $43.5 million in Series B funds on Tuesday. The funding round was led by Tencent. Other investors — Universi...
19.04.2022Free Market Health Secures $13.5M for Advance Specialty Pharmacy EcosystemWhat You Should Know: Free Market Health, a Pittsburgh-based healthcare technology company transforming the specialty pharmacy ecosystem with a care-driven marketplace platform, today announced its $13.5M in Series A financing led by Alta P...
11.01.2022Transcarent Raises $200M to Expand Care Platform for Self-Insured EmployersWhat You Should Know: – Transcarent, a new and different health and care experience company for employees of self-insured employers and their families, today announced a $200M Series C round led by Kinnevik and Human Capital, with participa...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In